收藏切换
Harmonization of the disintegration test between Chinese Pharmacopoeia and ICH Q4B Annex 5(R1)
收藏切换
Ying GENG1, Xiao-fen WANG2, Ning-yi WEI1, Qi-ming ZHANG1, Xin-yi XU3, Yue SHANG3, Yu WU4, Zi-feng ZHU5, Ping LIAO6, Quan YANG7, Gang HOU8, Tian-shou YANG2, *, Hua CHEN1, *
Chinese Journal of New Drugs | 2026, 35(9) : 911 - 919
Less
收藏切换
Chinese Journal of New Drugs | 2026, 35(9): 911-919
Harmonization of the disintegration test between Chinese Pharmacopoeia and ICH Q4B Annex 5(R1)
Full
Ying GENG1, Xiao-fen WANG2, Ning-yi WEI1, Qi-ming ZHANG1, Xin-yi XU3, Yue SHANG3, Yu WU4, Zi-feng ZHU5, Ping LIAO6, Quan YANG7, Gang HOU8, Tian-shou YANG2, *, Hua CHEN1, *
Affiliations
  • 1National Institutes for Food and Drug Control, Beijing 102629, China
  • 2Guyuan City Inspection and Testing Center for Market Regulation, Guyuan 756000, China
  • 3Chinese Pharmacopoeia Commission, Beijing 100061, China
  • 4Tianjin Tianda Tianfa Technology Co., Ltd., Tianjin 300392, China
  • 5Milestone Pharma, Nanjing 210061, China
  • 6Shanghai Center of Drug Evaluation and Inspection, Shanghai 201210, China
  • 7China Novartis Institutes for Biomedical Research Co., Ltd., Shanghai 201203, China
  • 8Bristol-Myers Squibb (China) Investment Co., Ltd., Shanghai 200020, China
Published: 2026-05-15 doi: 10.20251/j.cnki.1003-3734.2026.09.003
Outline
收藏切换

The disintegration test is a critical method and means for controlling the critical quality attributes of solid dosage forms. The International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH) harmonized the disintegration test methods of the United States Pharmacopeia (USP), European Pharmacopoeia (EP), and Japanese Pharmacopoeia (JP), resulting in the ICH Q4B Guideline Annex 5, which allows for mutual recognition within the ICH region. The 〈0921 Disintegration Test〉 in the 2025 edition of the Chinese Pharmacopoeia (ChP) has been harmonized with ICH Q4B Annex 5 (R1), achieving consistency with respect to apparatus and general procedure; acceptance criteria according to ICH and CHP are described in parallel; and the requirements for specific dosage forms as per the 2020 edition were retained. Additionally, the framework of 〈0921 Disintegration Test〉 has been revised to align with the ICH guideline, ensuring harmonization with international standards. This revision not only considers the historical inheritance of the Chinese Pharmacopoeia and the practical needs of China's pharmaceutical industry but also achieves international harmonization. This article provides a detailed comparison of the differences in apparatus and procedure between 〈0921 Disintegration Test〉 in the Chinese Pharmacopoeia and ICH Q4B Annex 5 (R1). Research on the harmonization of disintegration test methods across the ICH tripartite regions (EP, USP, JP) was carried out, including the comparison of disintegration test results, investigation of statistical data simulation for acceptance criteria, and the interpretation of the background, approach, and considerations behind the harmonization of 〈0921 Disintegration Test〉 with ICH. The aim is to enhance the understanding of the revisions to the 〈0921 Disintegration Test〉 in the 2025 edition and provide supportive reference for both the pharmaceutical industry and regulatory authorities.

Chinese Pharmacopoeia  /  ICH Q4B Appendix 5 (R1)  /  disintegration time limit inspection method  /  international harmonization  /  statistical simulation
耿颖, 王晓芬, 魏宁漪, 张启明, 徐昕怡, 尚悦, 吴娱, 朱子丰, 廖萍, 杨泉, 侯刚, 杨天寿, 陈华. 《中华人民共和国药典》崩解时限检查法与ICH Q4B附录5(R1)通则协调. 中国新药杂志, 2026 , 35 (9) : 911 -919 . DOI: 10.20251/j.cnki.1003-3734.2026.09.003
Ying GENG, Xiao-fen WANG, Ning-yi WEI, Qi-ming ZHANG, Xin-yi XU, Yue SHANG, Yu WU, Zi-feng ZHU, Ping LIAO, Quan YANG, Gang HOU, Tian-shou YANG, Hua CHEN. Harmonization of the disintegration test between Chinese Pharmacopoeia and ICH Q4B Annex 5(R1)[J]. Chinese Journal of New Drugs, 2026 , 35 (9) : 911 -919 . DOI: 10.20251/j.cnki.1003-3734.2026.09.003
Year 2026 volume 35 Issue 9
54
8
Cite this Article
BibTeX
Article Info
doi: 10.20251/j.cnki.1003-3734.2026.09.003
  • Online Date:2026-10-26
  • Published:2026-05-15
Article Data
Affiliations
History
  • Accepted:2025-10-23
Funding
Affiliations
    1National Institutes for Food and Drug Control, Beijing 102629, China
    2Guyuan City Inspection and Testing Center for Market Regulation, Guyuan 756000, China
    3Chinese Pharmacopoeia Commission, Beijing 100061, China
    4Tianjin Tianda Tianfa Technology Co., Ltd., Tianjin 300392, China
    5Milestone Pharma, Nanjing 210061, China
    6Shanghai Center of Drug Evaluation and Inspection, Shanghai 201210, China
    7China Novartis Institutes for Biomedical Research Co., Ltd., Shanghai 201203, China
    8Bristol-Myers Squibb (China) Investment Co., Ltd., Shanghai 200020, China
References
Share
https://castjournals.cast.org.cn/joweb/zgxyzz/EN/10.20251/j.cnki.1003-3734.2026.09.003
Share to
QR

Scan QR to access full text

Cite this article
BibTeX
Citations
表12种不同金属材料的力学参数
科
Family
属数
Number of
genus
种数
Number of
species
占总种数比例
Percentage of
total species (%)
属
Genus
种数
Number of
species
占总种数比例
Percentage of total
species (%)
鹅膏菌科Amanitaceae 2 11 5.26 鹅膏菌属 Amanita 10 4.78
小菇科 Mycenaceae 2 12 5.74 丝盖伞属 Inocybe 5 2.39
多孔菌科 Polyporaceae 8 14 6.70 蜡蘑属 Laccaria 5 2.39
红菇科 Russulaceae 3 23 11.00 小皮伞属 Marasmius 6 2.87
小菇属 Mycena 11 5.26
光柄菇属 Pluteus 5 2.39
红菇属 Russula 17 8.13
栓菌属 Trametes 5 2.39
关闭全屏
  • BibTeX
  • EndNote
  • RefWorks
  • TxT